Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameImmunotech-B
Stock Code06978
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities中國一家領先的細胞免疫治療生物醫藥公司,逾13年來專注於T細胞免疫治療藥物研發和商業化,核心在研產品EAL®為中國首款獲准進入II期臨床試驗的細胞免疫治療產品。
Listing Date2020-07-10
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市北京經濟技術開發區康定街1號國盛科技園1號樓8層
Business Address (Hong Kong)香港銅鑼灣勿地臣街1號時代廣場二座31樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteeaal.net
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 11.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size1,000 shares
Entry ThresholdHK$ 11,000
Par ValueTo be extracted
Offer Period2020-06-29 to 2020-07-03
Global Offering Shares100,000,000 shares
HK Public Offer Shares (Initial)10,000,000 shares (10.0%)
Public Offer Lots (Initial)10,000lots (Pool A5,000lots,Pool B5,000lots)
International Placing Shares (Initial)90,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO500,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share28.1%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,100,000,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 11,000
2 lots 2,000 HK$ 22,000
3 lots 3,000 HK$ 33,000
4 lots 4,000 HK$ 44,000
5 lots 5,000 HK$ 55,000
6 lots 6,000 HK$ 66,000
7 lots 7,000 HK$ 77,000
8 lots 8,000 HK$ 88,000
9 lots 9,000 HK$ 99,000
10 lots 10,000 HK$ 110,000
15 lots 15,000 HK$ 165,000
20 lots 20,000 HK$ 220,000
25 lots 25,000 HK$ 275,000
30 lots 30,000 HK$ 330,000
35 lots 35,000 HK$ 385,000
40 lots 40,000 HK$ 440,000
45 lots 45,000 HK$ 495,000
50 lots 50,000 HK$ 550,000
60 lots 60,000 HK$ 660,000
70 lots 70,000 HK$ 770,000
80 lots 80,000 HK$ 880,000
90 lots 90,000 HK$ 990,000
100 lots 100,000 HK$ 1,100,000
150 lots 150,000 HK$ 1,650,000
200 lots 200,000 HK$ 2,200,000
250 lots 250,000 HK$ 2,750,000
300 lots 300,000 HK$ 3,300,000
350 lots 350,000 HK$ 3,850,000
400 lots 400,000 HK$ 4,400,000
450 lots 450,000 HK$ 4,950,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
500 lots 500,000 HK$ 5,500,000
600 lots 600,000 HK$ 6,600,000
700 lots 700,000 HK$ 7,700,000
800 lots 800,000 HK$ 8,800,000
900 lots 900,000 HK$ 9,900,000
1,000 lots 1,000,000 HK$ 11,000,000
1,500 lots 1,500,000 HK$ 16,500,000
2,000 lots 2,000,000 HK$ 22,000,000
2,500 lots 2,500,000 HK$ 27,500,000
3,000 lots 3,000,000 HK$ 33,000,000
3,500 lots 3,500,000 HK$ 38,500,000
4,000 lots 4,000,000 HK$ 44,000,000
4,500 lots 4,500,000 HK$ 49,500,000
5,000 lots 5,000,000 HK$ 55,000,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 723M
Est. Threshold HK$ 9.37B
Analysis Result HK market cap below threshold, need +1196%

Valuation & Financials

Market Cap (at Offer Price)HK$ 5,375,000,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损人民币109.1百万元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 74,800,000
Listing Expenses / Funds Raised~6.8%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20182019
Other income and gains, net 8,0766,316
Administrative expenses -11,666-27,760
Operating profit -33,753-106,984
Net finance costs -1,135-2,070
Profit before tax -34,888-109,054
Income tax expense 00
Profit for the year -34,888-109,054
Profit attributable to owners -34,766-108,801
Balance Sheet
Item 20182019
Cash and cash equivalents 128,332282,247
Inventories 2,2914,810
Total current assets 185,761308,150
Total current liabilities 19,024206,170
Total equity 216,297170,335
Equity attributable to owners 214,651168,942
Cash Flow Statement
Item 20182019
Net cash from operating activities -44,079-95,469
Net cash from investing activities -50,40025,741
Net cash from financing activities 214,447217,209
Net increase in cash 119,968147,481
Depreciation of PP&E 4,17210,590
Amortisation of intangible assets 341355
Purchase of PP&E -35,070-13,762
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 15.48
First Day OpenHK$ 13.4
First Day Change40.73%
First Day Volume73620500.0
First Day Turnover1099240000.0
Use of Proceeds
1、約34.2%的所得款項凈額或350.2百萬港元用于投資EAL正在進行的臨床試驗及商業化; 2、約18.9%的所得款項凈額或193.5百萬港元用于擴展EAL的臨床適應癥(不包括肝癌),包括研發開支及就EAL持續技術創新設立新研發中心的建設成本; 3、約33.2%的所得款項凈額或340.0百萬港元用于投資CAR-T-19及TCR-T在研產品系列的臨床試驗,主要包括研發開支; 4、約8.7%的所得款項凈額或89.1百萬港元用于投資我們產品管線中其他在研產品的開發; 5、約5.0%的所得款項凈額或51.2百萬港元用作營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
建银国际金融有限公司 CE AJO225 Guosen Securities (HK) Capital Company Limited CE AUX600
Overall Coordinators (3)
建银国际金融有限公司 CE AJO225 Guosen Securities (HK) Capital Company Limited CE AUX600 海通国际证券有限公司 CE AAF806
Joint Bookrunners (13)
建银国际金融有限公司 CE AJO225 Guosen Securities (HK) Capital Company Limited CE AUX600 海通国际证券有限公司 CE AAF806 农银国际证券有限公司 CE ACX411 交银国际证券有限公司 CE APJ121 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 民银证券有限公司 CE APU820 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 国泰君安证券(香港)有限公司 CE ABY236 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 ZHONGRONG PT SECURITIES LIMITED CE AAV553 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Joint Lead Managers (18)
建银国际金融有限公司 CE AJO225 Guosen Securities (HK) Capital Company Limited CE AUX600 海通国际证券有限公司 CE AAF806 农银国际证券有限公司 CE ACX411 FTFT International Securities and Futures Limited CE ATR516 交银国际证券有限公司 CE APJ121 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 民银证券有限公司 CE APU820 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 富途证券国际(香港)有限公司 CE AZT137 国泰君安证券(香港)有限公司 CE ABY236 Wanhai Securities (HK) Limited CE ADS061 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 JOY RICH SECURITIES INVESTMENT LIMITED CE BIH924 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 ZHONGRONG PT SECURITIES LIMITED CE AAV553 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 I WIN SECURITIES LIMITED CE BJB315

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Poly Platinum Enterprises Limited 155,001,000 HKD — 14.10% — 6 months 2021-01-10
2 季洪昌 38,742,000 HKD — 3.50% — 6 months 2021-01-10
3 天士力(香港)医药投资有限公司 76,714,000 HKD — 7.00% — 6 months 2021-01-10
4 中国联塑集团控股有限公司 38,742,000 HKD — 3.50% — 6 months 2021-01-10

Directors & Management

PositionChinese nameEnglish Name
Chairman譚錚—
Company Secretary尹夢洋、梁瑞冰—
No director data available.

Major Shareholders

Major Shareholders & Holdings譚錚(透過Tan Zheng Ltd)持股36.10%,鄭鉉哲(透過Evodevo)持股26.99%,張蓓妮(透過Bei Ni Ltd)持股6.13%,大灣區共同家園發展基金有限合夥(透過Poly Platinum)持股6.69%。
About this page

This page shows Immunotech-B (06978) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect